Insight

Chris Boshoff: Pfizer’s Updates from the Second Quarter

Chris Boshoff/LinkedIn

Aug 5, 2025, 12:52

Chris Boshoff: Pfizer’s Updates from the Second Quarter

Chris Boshoff, Chief Scientific Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:

“We had a strong Second-Quarter at Pfizer and I want to thank everyone involved in advancing breakthrough science.

The R&D organization has continued progressing the pipeline with focus and rigor, inspired by the positive impact our work is having in the lives of people globally. I’m proud to share a few of the highlights from the last quarter:

At ASCO, we shared the first combination data for our BCMA-directed bispecific antibody in newly diagnosed Multiple Myeloma patients, and promising Phase 1 results for combination therapy with our investigational IB6-targeting vedotin ADC in Lung Cancer.

This quarter we also shared positive topline data from our Phase 3 study of our once-weekly subcutaneous treatment in hemophilia A or B with inhibitors. Despite the scientific progress made in hemophilia treatment, many people living with this debilitating and rare disorder continue to experience bleeding episodes.

At our earnings call, we shared updates on our second-generation investigational vaccine against C. Difficile infection, an area where we could potentially make important inroads with no currently approved vaccines to help prevent primary or recurrent C. diff infection and a high unmet need. We look forward to starting Phase 3 in the coming months.

More than halfway through this year, I’m proud of what’s been accomplished and I’m looking forward to the journey ahead, as we deliver more breakthroughs for those we serve.”

Chris Boshoff